



### Sabril® (vigabatrin) – First-time generic

- Par has received [FDA approval](#) of its [AB-rated](#) generic version of Lundbeck Pharmaceuticals' [Sabril \(vigabatrin\)](#) 500 mg powder packets for oral solution.
- Sabril is indicated as adjunctive therapy for adults and pediatric patients 10 years of age and older with refractory complex partial seizures who have inadequately responded to several alternative treatments and as monotherapy for pediatric patients with infantile spasms 1 month to 2 years of age.
  - Sabril is indicated for both indications only for patients for whom the potential benefits outweigh the potential risk of vision loss.
  - Sabril is not indicated as a first line agent for complex partial seizures.
- Sabril is also available as a brand name 500 mg tablet.
- Sabril carries a boxed warning for permanent vision loss.
- Par's launch plans for generic Sabril are pending.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.